Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550238 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 459
- Enrollment target
NCT00550238 is a Phase 3 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 459 participants.
The verdict
NCT00550238, a Phase 3 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 459 participants
- Enrollment target
Study Summary
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
Interventions
- DRUG Pimavanserin tartrate (ACP-103)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2007-07 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550238
The ClinicalTrials.gov registry entry for NCT00550238 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin tartrate (ACP-103) is the first listed.
NCT00550238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550238 about?
NCT00550238 is a clinical study titled "A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis". To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
What is the current status of trial NCT00550238?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 459 participants. The study started on 2007-07. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT00550238?
The interventions under investigation include: Pimavanserin tartrate (ACP-103) (DRUG).
Who is sponsoring clinical trial NCT00550238?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.